ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
ViroPharma, in Exton, Pa., has reached an agreement to acquire Lev Pharmaceuticals, a New York City-based biopharmaceutical firm focused on developing treatments for inflammatory diseases, for an up-front payment of $442.9 million. Lev's Cinryze, a C1 inhibitor therapy for patients with hereditary angiodema, is currently under FDA review. Lev shareholders are also eligible for up to $175 million in regulatory and commercial milestone payments.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter